中国临床药理学杂志2017，Vol.33Issue(13)：1194-1197,4.DOI:10.13699/j.cnki.1001-6821.2017.13.008
多西他赛注射剂联合吡柔比星注射剂治疗乳腺癌的临床研究
Clinical trial of combination therapy with decetaxel injection and pirarubicin injection in the treatment of breast cancer
摘要
Abstract
Objective To observe the clinical efficacy of docetaxel and pirarubicin in the treatment of breast cancer and its effect on the expressions of ChemoCentryx chemokine receptor (CCX-CKR) and vascular endothelial growth factor (VEGF).Methods Fifty patients with breast cancer were randomly divided into control group (n =25) and treatment group (n =25).The treatment group received 50 mg · m-2 of pirarubicin intravenously on the first day,and received a 60 min continuous infusion (a 21 days-course) with 75 mg · m-2 of docetaxel 30 min after the first injection.The control group was given 50 mg · m-2 of pirarubicin intravenously on the first day,and 15 mg · m-2 of avastin was infused intravenously 30 min after of infusion for 60 min.Both groups take it every 21 days for a course of treatment,and they were treated for 2 courses.The positive expression of CCX-CKR and VEGF was detected by immunohistochemical method,and the clinical efficacy and adverse drug reactions (ADRs) of the two groups were analyzed.Results After treatment,the total effective rates of the two groups were 72.00％ (18/25 cases) and 60.00％ (15/25 cases),respectively.There was no significant difference (P ＞ 0.05) between the treatment group and the control group.The positive rates of CCX-CKR in treatment group and control group were 32.00％ and 44.00％ respectively,and the positive rate of VEGF was 52.00％ and 64.00％,respectively.There was no significant difference between the two groups (P ＞0.05).In the control group,ADR were nausea and vomiting occurred in 15 cases,alopecia in 8 cases,anemia in 5 cases,leukopenia in 14 cases,thrombocytopenia in 10 cases,diarrhea in 7 cases.And in treatment group,ADRs were nausea and vomiting in 12 cases,5 cases of alopecia,anemia in 4 cases,12 cases of leukopenia,7 cases of thrombocytopenia,3 cases of diarrhea,with no statistically significant difference (P ＞ 0.05).Conclusion Docetaxel combined with pirarubicin in the treatment of breast cancer is effective,and the therapy can markedly reduce the CCX-CKR,VEGF positive expression rate,and with low adverse reaction rate.关键词
多西他赛/吡柔比星/乳腺癌/ChemoCentryx趋化因子受体/血管内皮生长因子Key words
docetaxel/pirarubicin/breast cancer/ChemoCentryx chemokine receptor/vascular endothelial growth factor分类
医药卫生引用本文复制引用
周儒兵,李伟,周双容..多西他赛注射剂联合吡柔比星注射剂治疗乳腺癌的临床研究[J].中国临床药理学杂志,2017,33(13):1194-1197,4.基金项目
重庆市沙坪坝区科委基金资助项目(jcd201505) （jcd201505）
